GlassScriptPhysician profile
John R Guzek
NPI 1861460545
$7,038.68
in general payments reported to CMS, 2019-2025
45 companies · $2,694 in 2025
The $2,694 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.44 · 2023: $1,708 · 2024: $2,612 · 2025: $2,694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,014.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,014.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,077.72 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $920.76 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $652.58 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $360.63 | 2023-2025 | Xifaxan, Trulance |
| Lundbeck LLC | $342.85 | 2023-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $326.10 | 2023-2025 | |
| Abbott Laboratories | $256.31 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $253.44 | 2023-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $250.74 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $226.88 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $214.35 | 2023-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $186.42 | 2023-2024 | Austedo Xr, Austedo |
| Pfizer INC. | $173.99 | 2023-2025 | |
| Esperion Therapeutics, INC. | $172.99 | 2024-2025 | Nexletol |
| Sumitomo Pharma America, INC. | $135.53 | 2023-2025 | Gemtesa |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $129.27 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $125.55 | 2023-2025 | Eliquis, Camzyos |
| Aimmune Therapeutics, INC. | $118.75 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $103.08 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.95 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $73.59 | 2023-2024 | Belsomra, Verquvo, Gardasil 9 |
| Dexcom, INC. | $69.49 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.44 | 2023-2025 | Jardiance, Tradjenta |
| Shield Therapeutics INC | $64.74 | 2024 | |
| Ironwood Pharmaceuticals, INC | $64.51 | 2023-2024 | Linzess |
| Verona Pharma, INC. | $58.23 | 2025 | Ohtuvayre |
| Kowa Pharmaceuticals America, INC. | $53.29 | 2023-2025 | Seglentis, Livalo, Zoryve |
| Axsome Therapeutics, INC. | $49.67 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $46.46 | 2025 | Voquezna |
| Prescient Lab Services, LLC | $44.07 | 2025 | Avertd Amplification Mix, Avertd Biofilmchip Microarray Magazine, Prescript |
| Ucb, INC. | $38.52 | 2023-2024 | Nayzilam |
| Indivior INC. | $36.38 | 2024-2025 | Sublocade |
| Exact Sciences Corporation | $35.74 | 2024 | Cologuard Collection Kit |
| Hikma Pharmaceuticals USA | $24.44 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $23.78 | 2025 | Uptravi, Opsumit |
| Scpharmaceuticals INC. | $20.76 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.67 | 2024 | Trintellix |
| Nestle Healthcare Nutrition INC. | $19.20 | 2023 | |
| Vanda Pharmaceuticals INC. | $18.10 | 2025 | Fanapt |
| Optinose US, INC. | $15.97 | 2024 | |
| Sanofi-Aventis U.S. LLC | $15.34 | 2023 | |
| Amarin Pharma, INC. | $15.04 | 2023 | |
| Tactile Systems Technology INC | $15.02 | 2025 | Nimbl, Flexitouch Plus |
| Teleflex LLC | $14.78 | 2024 | Urolift |
| Janssen Pharmaceuticals, INC | $13.56 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Guzek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.